(19)
(11) EP 3 583 122 A1

(12)

(43) Date of publication:
25.12.2019 Bulletin 2019/52

(21) Application number: 18754083.6

(22) Date of filing: 17.02.2018
(51) International Patent Classification (IPC): 
C07K 16/00(2006.01)
C07K 16/10(2006.01)
(86) International application number:
PCT/US2018/018559
(87) International publication number:
WO 2018/152452 (23.08.2018 Gazette 2018/34)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD TN

(30) Priority: 17.02.2017 US 201762460200 P

(71) Applicants:
  • Mapp Biopharmaceutical, Inc.
    San Diego, CA 92121 (US)
  • Albert Einstein College of Medicine, Inc.
    Bronx, NY 10461 (US)
  • Adimab, LLC
    Lebanon, NH 03766 (US)

(72) Inventors:
  • BORNHOLDT, Zachary, A.
    Encinitas, CA 92024 (US)
  • ZEITLIN, Larry
    San Diego, CA 92128 (US)
  • CHANDRAN, Kartik
    Brooklyn, NY 11201 (US)
  • WEC, Anna
    Lebanon, NH 03766 (US)
  • WALKER, Laura
    Norwich, VT 05055 (US)

(74) Representative: Latscha Schöllhorn Partner AG 
Grellingerstrasse 60
4052 Basel
4052 Basel (CH)

   


(54) MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS